MiMedx Group (NASDAQ:MDXG) Reaches New 52-Week Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $4.35 and last traded at $4.3550, with a volume of 156572 shares. The stock had previously closed at $4.38.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MDXG. Mizuho cut their target price on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 17th. Cantor Fitzgerald lowered their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Citizens Jmp began coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating and a $10.00 price objective for the company. UBS Group set a $10.00 target price on shares of MiMedx Group in a report on Monday, February 23rd. Finally, Lake Street Capital decreased their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, MiMedx Group has an average rating of “Moderate Buy” and a consensus price target of $9.60.

MiMedx Group Trading Down 0.6%

The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. The firm’s 50 day moving average price is $5.28 and its 200 day moving average price is $6.42. The stock has a market capitalization of $647.02 million, a P/E ratio of 13.61 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. As a group, equities research analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds have recently made changes to their positions in the business. World Investment Advisors bought a new stake in MiMedx Group in the fourth quarter valued at $173,000. Virtu Financial LLC bought a new stake in shares of MiMedx Group during the 4th quarter valued at about $78,000. Invesco Ltd. increased its position in shares of MiMedx Group by 5.9% during the fourth quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock valued at $574,000 after buying an additional 4,708 shares during the period. Corient Private Wealth LLC raised its stake in MiMedx Group by 26.0% in the fourth quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock worth $316,000 after buying an additional 9,614 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV raised its stake in MiMedx Group by 33.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock worth $141,000 after buying an additional 5,236 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.